Newsletters

[Genentech ] Genentech announced that the US FDA has accepted and granted Priority Review to its sBLA for Tecentriq® (atezolizumab) and Tecentriq Hybreza® in combination with chemotherapy for stage III dMMR/MSI-H colon cancer.

[Nature] Scientists identified dHuR as a molecular glue degrader of human antigen R (HuR), an RNA-binding protein that drives tumour growth, invasion, and therapy resistance.

[Journal of Translational Medicine] Investigators show that Sirtuin-3 (SIRT3) drives gastric cancer progression and cisplatin resistance by stabilizing the mitochondrial transporter SLC25A6, revealing a metabolic pathway that could be targeted to overcome chemoresistance.

[Msystems] Researchers demonstrated a progressive decline of harmane levels in the gut from healthy individuals to advanced adenoma and colorectal cancer (CRC) patients, suggesting its potential protective role in CRC development.

[Journal of Agricultural and Food Chemistry] The authors found that 48-week PCB138 exposure induced ileal damage, inflammation, oxidative stress, and necroptosis in mice, which were mitigated by theabrownin intervention.

[Journal of Enzyme Inhibition and Medicinal Chemistry] Scientists systematically evaluated the effects of combining lidocaine with sorafenib and/or GW5074 in colorectal cancer cell lines. They aimed to determine whether these regimens enhance cytotoxicity, overcome resistance associated with targeted therapies, and modulate cell death pathways.

[Scientific Reports] Researchers show that low KIF4A expression is associated with aggressive gastric cancer, poorer survival, and activation of epithelial–mesenchymal transition programs.

[Scientific Reports] Investigators evaluated the therapeutic potential of a commercially available probiotic formulation using a human gut-on-a-chip model that mimics the physiodynamic intestinal microenvironment.

[Cancer Letters] Scientists provide a comprehensive analysis of the evolving landscape of immunotherapies designed to target colorectal cancer stem-like cells.

[Signal Transduction and Targeted Therapy] Researchers applied 3D patient-derived, metastatic human mammary organoids to model apoptosis resistance, necroptosis, and inflammatory signaling using single-cell CITE-sequencing, time-lapse live cell brightfield, and immunofluorescent confocal microscopy.

[Cell Reports] Investigators presented an extensive catalog of mutational signatures induced by a panel of environmental carcinogens using human tissue-derived organoids coupled with high-fidelity duplex sequencing

[Journal of Translational Medicine] Scientists established a robust and clinically validated patient-derived organoid platform for hepatic malignancies that accurately predicts patient-specific drug responses.